Unity Biotechnology Inc Total Liabilities
Unity Biotechnology Inc total liabilities. Based on the latest financial reports, Unity Biotechnology Inc (UBX) has total liabilities worth $30.55 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Unity Biotechnology Inc (UBX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Unity Biotechnology Inc (2016–2024)
Total liabilities of Unity Biotechnology Inc from 2016 to 2024. This chart illustrates how Unity Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Unity Biotechnology Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Unity Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Unity Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Australian Silica Quartz Group Ltd
F:4B4
|
Germany | €254.55K |
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
USA | $12.89 Million |
|
Innovotech Inc
V:IOT
|
Canada | CA$993.81K |
|
Mustang Bio Inc
NASDAQ:MBIO
|
USA | $8.07 Million |
|
Kridhan Infra Limited
NSE:KRIDHANINF
|
India | Rs2.68 Billion |
|
Ordissimo
PA:ALORD
|
France | €3.91 Million |
|
Videndum Plc
LSE:VID
|
UK | GBX253.00 Million |
|
Cheetah Net Supply Chain Service Inc. Class A Common Stock
NASDAQ:CTNT
|
USA | $2.19 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Unity Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see UBX asset base.
Liquidity & Leverage Metrics
Unity Biotechnology Inc Total Liabilities Ratios Explained
Unity Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -149.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Unity Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Unity Biotechnology Inc (2016–2024)
The table below shows the annual total liabilities of Unity Biotechnology Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.17 Million | -16.42% |
| 2023-12-31 | $37.29 Million | -35.15% |
| 2022-12-31 | $57.50 Million | -11.73% |
| 2021-12-31 | $65.14 Million | -11.30% |
| 2020-12-31 | $73.44 Million | +140.67% |
| 2019-12-31 | $30.51 Million | +47.54% |
| 2018-12-31 | $20.68 Million | +84.97% |
| 2017-12-31 | $11.18 Million | -91.91% |
| 2016-12-31 | $138.18 Million | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more